Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, includin… Read more
Q linea AB (QLINEA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.118x
Based on the latest financial reports, Q linea AB (QLINEA) has a cash flow conversion efficiency ratio of -0.118x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-39.80 Million) by net assets (Skr338.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Q linea AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Q linea AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Q linea AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q linea AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MCH Group AG
SW:MCHN
|
0.108x |
|
Original BioMedicals Co., Ltd.
TWO:6483
|
-0.208x |
|
TMT Steel Public Company Limited
BK:TMT
|
0.022x |
|
J8D0
F:J8D0
|
N/A |
|
Perfect Medical Industry Co., Ltd.
TWO:6543
|
0.047x |
|
Rumble Resources Ltd
AU:RTR
|
-0.030x |
|
Kirloskar Electric Company Limited
NSE:KECL
|
-7.328x |
|
Gongin Precision Industrial Co Ltd
TWO:3178
|
0.029x |
Annual Cash Flow Conversion Efficiency for Q linea AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Q linea AB from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr338.00 Million | Skr-162.12 Million | -0.480x | -107.22% |
| 2024-12-31 | Skr-27.46 Million | Skr-182.50 Million | 6.647x | +651.58% |
| 2023-12-31 | Skr189.64 Million | Skr-228.52 Million | -1.205x | +22.36% |
| 2022-12-31 | Skr161.63 Million | Skr-250.86 Million | -1.552x | -162.15% |
| 2021-12-31 | Skr430.79 Million | Skr-255.05 Million | -0.592x | +5.14% |
| 2020-12-31 | Skr380.20 Million | Skr-237.31 Million | -0.624x | -25.36% |
| 2019-12-31 | Skr340.94 Million | Skr-169.76 Million | -0.498x | -108.34% |
| 2018-12-31 | Skr513.46 Million | Skr-122.71 Million | -0.239x | +99.43% |
| 2017-12-31 | Skr1.51 Million | Skr-62.87 Million | -41.577x | -565.28% |
| 2016-12-31 | Skr8.45 Million | Skr-52.83 Million | -6.250x | -- |